Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study
Walter Ling, Vijay R Nadipelli, Caitlyn T Solem, Naoko A Ronquest, Yu-Chen Yeh, Susan M Learned, Vishaal Mehra, Christian Heidbreder, Walter Ling, Vijay R Nadipelli, Caitlyn T Solem, Naoko A Ronquest, Yu-Chen Yeh, Susan M Learned, Vishaal Mehra, Christian Heidbreder
Abstract
Objective: Opioid use disorder (OUD) is associated with physical, social, psychological, and economic burden. This analysis assessed the effects of RBP-6000, referred to as BUP-XR (extended-release buprenorphine), a subcutaneously injected, monthly buprenorphine treatment for OUD compared with placebo on patient-centered outcomes measuring meaningful life changes.
Methods: Patient-centered outcomes were collected in a 24-week, phase 3, placebo-controlled study assessing the efficacy, safety, and tolerability of BUP-XR 300/300 mg (6 × 300 mg) and 300/100 mg (2 × 300 mg followed by 4 × 100 mg) injections in treatment-seeking participants with moderate-to-severe OUD. Measures included the EQ-5D-5L, SF-36v2, Medication Satisfaction Questionnaire, employment/insurance status, and healthcare resource utilization (HCRU). Changes from baseline to end of study were compared across treatment arms, using mixed models for repeated measures.
Results: Participants receiving BUP-XR (n = 389) versus placebo (n = 98) had significantly greater changes from baseline on the EQ-5D-5L index (300/300 mg: difference = 0.0636, P = 0.003), EQ-5D-5L visual analog scale (300/300 mg: difference = 5.9, P = 0.017; 300/100 mg: difference = 7.7, P = 0.002), and SF-36v2 physical component summary score (300/300 mg: difference = 3.8, P < 0.001; 300/100 mg: difference = 3.2, P = 0.002). Satisfaction was significantly higher for participants receiving BUP-XR 300/300 mg (88%, P < 0.001) and 300/100 mg (88%, P < 0.001) than placebo (46%). Employment and percentage of insured participants increased by 10.8% and 4.1% with BUP-XR 300/300 mg and 10.0% and 4.7% with 300/100 mg but decreased by 12.6% and 8.4% with placebo. Participants receiving BUP-XR compared with placebo had significantly fewer hospital days per person-year observed.
Conclusions: These results show the feasibility of measuring patient-centered life changes in substance use disorder clinical studies. Participants receiving up to 6 monthly injections of BUP-XR, compared with placebo, reported better health, increased medication satisfaction, increased employment, and decreased healthcare utilization.
Conflict of interest statement
The authors report no conflicts of interest
Figures
References
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). USA: American Psychiatric Publishing; 2013.
- Bray JW, Aden B, Eggman AA, et al. Quality of life as an outcome of opioid use disorder treatment: A systematic review. J Subst Abuse Treat 2017; 76:88–93.
- Carpentier PJ, Krabbe PF, van Gogh MT, et al. Psychiatric comorbidity reduces quality of life in chronic methadone maintained patients. Am J Addict 2009; 18:470–480.
- De Jong CA, Roozen HG, van Rossum LG, et al. High abstinence rates in heroin addicts by a new comprehensive treatment approach. Am J Addict 2007; 16:124–130.
- Fowler FJ, Jr, Levin CA, Sepucha KR. Informing and involving patients to improve the quality of medical decisions. Health Aff (Millwood) 2011; 30:699–706.
- Griffin ML, Bennett HE, Fitzmaurice GM, et al. Health-related quality of life among prescription opioid-dependent patients: Results from a multi-site study. Am J Addict 2015; 24:308–314.
- Haight BR, Learned SM, Laffont CM, et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2019.
- Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011; 20:1727–1736.
- Ling W, Farabee D, Liepa D, et al. The Treatment Effectiveness Assessment (TEA): An efficient, patient-centered instrument for evaluating progress in recovery from addiction. Subst Abuse Rehabil 2012; 3:129–136.
- Nosyk B, Guh DP, Sun H, et al. Health related quality of life trajectories of patients in opioid substitution treatment. Drug Alcohol Depend 2011; 118:259–264.
- Oviedo-Joekes E, Guh D, Brissette S, et al. Effectiveness of diacetylmorphine versus methadone for the treatment of opioid dependence in women. Drug Alcohol, Depend 2010; 111:50–57.
- Schafer A, Wittchen HU, Backmund M, et al. Psychopathological changes and quality of life in hepatitis C virus-infected, opioid-dependent patients during maintenance therapy. Addiction 2009; 104:630–640.
- Sittambalam CD, Vij R, Ferguson RP. Buprenorphine Outpatient Outcomes Project: can Suboxone be a viable outpatient option for heroin addiction? J Community Hosp Intern Med Perspect 2014; 4:
- SUBLOCADETM [package insert]. North Chesterfield, VA: Indivior Inc., 2018.
- U.S. Department of Health and Human Services. Opioid dependence: Developing depot buprenorphine products for treatment guidance for industry, draft guidance. Available at: Accessed May 1, 2018.
- Vernon MK, Revicki DA, Awad AG, et al. Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients. Schizophr Res 2010; 118:271–278.
- Ware J, Kosinski M, Bjorner J, et al. Determining important differences in scores. User's Manual for the SF-36v2 Health Survey. Lincoln, RI: Quality Metric; 2007.
- Ware JE, Kosinski M, Bjorner JB, et al. User's manual for the SF-36v2 Health Survey. Lincoln, RI: Quality Metric; 2008.
Source: PubMed